Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and its senior executives for potential violations of federal securities laws, particularly concerning the safety claims of its product Elevidys [1][2]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [3]. Allegations and Claims - The lawsuit alleges that Sarepta misrepresented the safety profile of Elevidys, claiming that the benefits outweighed the risks, while in reality, the treatment has been linked to fatal acute liver failure in some patients [3]. Stock Performance and Market Reaction - Following the announcement of a patient's death due to acute liver failure after receiving Elevidys, Sarepta's stock price dropped by $27.81, or over 27%, from $101.35 on March 17, 2025, to $73.54 on March 18, 2025 [4]. - After a second patient death was reported on June 15, 2025, Sarepta's stock fell by $15.24, or more than 42%, from $36.18 on June 13, 2025, to $20.94 on June 16, 2025 [4]. - A third patient death related to Elevidys was reported on July 17, 2025, leading to a further decline of over 40% in the stock price on July 18, 2025 [5]. Legal Context - The lawsuit is pending in the U.S. District Court for the Southern District of New York, under the case caption Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 25-cv-05317 [2].
SRPT DEADLINE NOTICE: Sarepta Therapeutics, Inc. Investors are Notified of the August 25 Class Action Deadline -- Contact BFA Law if You Suffered Losses (NASDAQ:SRPT)